Genomic diagnostic tests that help to guide toward personalized treatment for cancer patients seized the stage at this year's American Society of Clinical Oncology (ASCO) conference in Chicago. Most prominently, a study of more than 10,000 women funded by the NIH's National Cancer Institute that reported results at last year's conference now offered the basis of dramatically revised ASCO guidelines limiting the use of chemotherapy in early stage breast cancer.